Targeted silencing of MAPK4 in ECs using small interfering RNA driven by the CD34 promoter effectively inhibited tumor angiogenesis and growth of NSCLC in vivo.<h4>Conclusion</h4>Our results reveal that MAPK4 plays an important role in the angiogenesis and development of NSCLC. Here, CD34 is linked to neoplasm.